Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 17;14(1):19103.
doi: 10.1038/s41598-024-70349-y.

Novel nomogram and risk stratification for peritoneal recurrence after curative resection in gastric cancer

Yingjiao Zhu #  1 , Hao Chen #  1 , Yahua Wu #  1 , Tao Jiang  1 , Xinli Wang  1 , Jianwei Zheng  1 , Xiaoyan Lin  2   3
Affiliations

Novel nomogram and risk stratification for peritoneal recurrence after curative resection in gastric cancer

Yingjiao Zhu et al. Sci Rep. .

Abstract

Peritoneal recurrence (PR) in gastric cancer after curative resection has poor prognosis. Therefore, we aimed to construct a nomogram to predict PR, and establish PR score for risk stratification to guide adjuvant chemotherapy. A total of 315 patients with gastric cancer after radical surgery were included, and randomly stratified into training group (n = 221) and validation group (n = 94). Univariate and multivariate analyses were used to determine predictive factors of PR. The nomogram was constructed to predict the risk of PR. We utilized the time-dependent area under the receiver operating characteristic (ROC) curves (AUCs), calibration curves, and decision curve analysis (DCA) to evaluate the performance of the nomogram. Multivariate analysis showed that tumor site, N stage, preoperative CEA, and postoperative CA199 were independent predictors of PR. A nomogram was constructed to predict PR based on these factors. The AUC value was 0.755 in the training group and 0.715 in the validation group. The calibration curves showed good agreement between prediction and observation in the training and validation groups. The decision curve analysis displayed a good net benefit of the nomogram. The novel PR score was developed and patients were stratified into the low-, medium-, and high -risk groups. For the high-risk group, postoperative adjuvant chemotherapy significantly improved patients' overall survival (OS) and disease-free survival (DFS). The establishment of nomogram facilitates the prediction of PR after radical gastrectomy, and a novel PR score may help guide adjuvant chemotherapy for gastric cancer.

Keywords: Adjuvant chemotherapy; Gastric cancer; Nomogram; Peritoneal recurrence; Risk stratification.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
The construction and evaluation of nomogram. The nomogram for predicting the risk of PR (A). The area under of receiver operating characteristic curve (B), decision curve (C) calibration curve (D) for predicting the risk of PR in the training cohort. The area under of receiver operating characteristic curve (E), decision curve (F) calibration curve (G) for predicting the risk of PR in the validation cohort.
Figure 2
Figure 2
Kaplan–Meier survival analysis for OS (A) and DFS (B) in different risk groups according to the PR score.
Figure 3
Figure 3
Kaplan–Meier survival curves for OS in gastric cancer patients stratified by chemotherapy in the low-risk group (A), medium-risk group (B), and high-risk group (C). Kaplan–Meier survival curves for DFS in gastric cancer patients stratified by chemotherapy in low-risk group (D), medium-risk group (E), and high-risk group (F).
See this image and copyright information in PMC

References

    1. Joshi, S. S. & Badgwell, B. D. Current treatment and recent progress in gastric cancer. CA Cancer J. Clin.71, 264–279 (2021). 10.3322/caac.21657 - DOI - PMC - PubMed
    1. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin.71, 209–249 (2021). 10.3322/caac.21660 - DOI - PubMed
    1. Alsina, M., Arrazubi, V., Diez, M. & Tabernero, J. Current developments in gastric cancer: From molecular profiling to treatment strategy. Nat. Rev. Gastroenterol. Hepatol.20, 155–170 (2023). 10.1038/s41575-022-00703-w - DOI - PubMed
    1. Wang, Y., Zhang, L., Yang, Y., Lu, S. & Chen, H. Progress of gastric cancer surgery in the era of precision medicine. Int. J. Biol. Sci.17, 1041–1049 (2021). 10.7150/ijbs.56735 - DOI - PMC - PubMed
    1. Kono, K. et al. Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: Experience from Singapore and Japan. Gastric Cancer20, 122–127 (2017). 10.1007/s10120-016-0660-y - DOI - PubMed